<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433354</url>
  </required_header>
  <id_info>
    <org_study_id>CAFQ056B2278</org_study_id>
    <secondary_id>2011-002379-40</secondary_id>
    <nct_id>NCT01433354</nct_id>
  </id_info>
  <brief_title>Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)</brief_title>
  <official_title>An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to generate long-term safety, tolerability and efficacy data for
      AFQ056 in eligible adolescent patients with FXS who have participated in the CAFQ056B2214
      study, the PK study CAFQ056B2131, or another study of AFQ056 which included FXS patients
      below 18 years of age provided the patient is at least 12 years of age at the time of entry
      into the current study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study treatment failed to demonstrate efficacy in target population in two other clinical
    studies (CAFQ056B2214 and CAFQ056A2212).
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Prior to first dose in extension study, Baseline (start of study treatment in extension study) to End of trial</time_frame>
    <description>Adverse events were summarized for the open-label treatment period, where the open-label treatment period is defined based on how AEs were collected and reported according to the manner in which participants entered the current study and which treatment (AFQ056 or placebo) they were receiving in the previous study.
AEs which were continuing from the core study or that started after the end of core study but prior to first dose of open-label study medication in the extension study for Category 1 participants are shown under 'Prior to Ext. first dose'.
AEs which started during the open-label treatment period are presented based on the last AFQ056 dose taken on or before the onset date of the AE (25 mg bid; 50 mg bid; 75 mg bid; or 100 mg bid). No efficacy data presented as study was terminated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Fragile X Syndrome</condition>
  <arm_group>
    <arm_group_label>AFQ056 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will initiate treatment with AFQ056 at a starting dose of 25 mg b.i.d. The dose will be titrated from 25 mg b.i.d to 50 mg b.i.d., 75 mg b.i.d. and 100 mg b.i.d. at weekly intervals. Dose adjustments (up- and down-titrations) will be permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose, not to exceed 100 mg b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFQ056</intervention_name>
    <description>The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.</description>
    <arm_group_label>AFQ056 Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1 patients:

          -  Must have completed study CAFQ056B2214 or another study of AFQ056 which included FXS
             patients below 18 years of age within one week of enrollment into the open-label
             study.

          -  Has a caregiver or caregivers who spend, on average, at least 6 hours per day with the
             patient , who is willing to and capable of supervising treatment, providing input into
             efficacy and safety assessments, and accompanying the patient to study visits.

          -  Group 2 patients:

          -  Must meet one of the following conditions:

          -  Completed Study CAFQ056B2131

          -  Completed Study CAFQ056B2214 or another study of AFQ056 which included FXS patients
             below 18 years of age but enrollment into the current study was delayed for more than
             a week.

          -  Discontinued prematurely from Study CAFQ056B2214 or another study of AFQ056 which
             included FXS patients below 18 years of age due to intolerability of the dosage in the
             patient's assigned treatment group.

          -  Has a caregiver or caregivers who spend, on average, at least 6 hours per day with the
             patient , who is willing to and capable of supervising treatment, providing input into
             efficacy and safety assessments, and accompanying the patient to study visits.

        Exclusion Criteria:

          -  Discontinuation from Study CAFQ056B2214 or CAFQ056B2131 or another study of AFQ056
             which included FXS patients below 18 years of age due to safety reasons

          -  Female patients who are sexually active at any time during the study

          -  Any advanced, severe or unstable disease

          -  History and/or presence of schizophrenia, bipolar disease, psychosis, confusional
             states and/or repeated hallucinations as per DSM-IV criteria

          -  History of suicidal behavior or considered a high suicidal risk

          -  History of severe self-injurious behavior

          -  History of uncontrolled seizure disorder or resistant to therapy within the past 2
             years (Patients who are clinically stable under anti-convulsant therapy for the past 2
             years are not excluded)

          -  History of clinically significant allergies requiring hospitalization or non-inhaled
             corticosteroid therapy (asthma, anaphylaxis, etc.)

          -  History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years, regardless of whether or
             not there is evidence of local recurrence or metastases

          -  Patients who are using (or used within 6 weeks before baseline) digoxin or warfarin

          -  Using (or used within 6 weeks before baseline) concomitant medications that are potent
             inhibitors or inducers of CYP3A4

          -  Using glutamatergic agents (riluzole, memantine, etc.) or lithium within 6 weeks of
             baseline

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Málaga</city>
        <state>Andalucia</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Cugat</city>
        <state>Cataluña</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spånga</city>
        <zip>16374</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH10 5HF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <results_first_submitted>September 14, 2015</results_first_submitted>
  <results_first_submitted_qc>September 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2015</results_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fragile X Syndrome</keyword>
  <keyword>Martin-Bell Syndrome</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>X-Linked</keyword>
  <keyword>Escalante's syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fragile X Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 28 centres in 13 countries.</recruitment_details>
      <pre_assignment_details>A total of 120 patients were enrolled, of which 119 received the study medication. Category 1 patients received AFQ056 in the core study and enrolled in the extension within 7 days of the core study; Category 2 included all other patients who were enrolled into the extension study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AFQ056</title>
          <description>Participants from a previous AFQ056 study who entered the open-label extension study were administered AFQ056 capsules at a starting dose of 25 milligram (mg) twice daily (bid) and then titrated to 50 mg bid, 75 mg bid and 100 mg bid at weekly intervals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119">120 enrolled of which 119 were administered drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants who received at least one dose of the study drug (AFQ056) during the study.</population>
      <group_list>
        <group group_id="B1">
          <title>AFQ056</title>
          <description>Participants from a previous AFQ056 study who entered the open-label extension study were administered AFQ056 capsules at a starting dose of 25 milligram (mg) twice daily (bid) and then titrated to 50 mg bid, 75 mg bid and 100 mg bid at weekly intervals.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>Adverse events were summarized for the open-label treatment period, where the open-label treatment period is defined based on how AEs were collected and reported according to the manner in which participants entered the current study and which treatment (AFQ056 or placebo) they were receiving in the previous study.
AEs which were continuing from the core study or that started after the end of core study but prior to first dose of open-label study medication in the extension study for Category 1 participants are shown under ‘Prior to Ext. first dose’.
AEs which started during the open-label treatment period are presented based on the last AFQ056 dose taken on or before the onset date of the AE (25 mg bid; 50 mg bid; 75 mg bid; or 100 mg bid). No efficacy data presented as study was terminated.</description>
        <time_frame>Prior to first dose in extension study, Baseline (start of study treatment in extension study) to End of trial</time_frame>
        <population>The analysis was performed in the safety set (SS) population, defined as participants who received at least one dose of study medication and had at least one safety assessment occurring after first dose of extension study medication. Here, ‘Number of Participants Analyzed’ signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AFQ056</title>
            <description>Total</description>
          </group>
          <group group_id="O2">
            <title>Prior to Ext. First Dose</title>
          </group>
          <group group_id="O3">
            <title>AFQ056 25 mg Bid</title>
          </group>
          <group group_id="O4">
            <title>AFQ056 50 mg Bid</title>
          </group>
          <group group_id="O5">
            <title>AFQ056 75 mg Bid</title>
          </group>
          <group group_id="O6">
            <title>AFQ056 100 mg Bid</title>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>Adverse events were summarized for the open-label treatment period, where the open-label treatment period is defined based on how AEs were collected and reported according to the manner in which participants entered the current study and which treatment (AFQ056 or placebo) they were receiving in the previous study.
AEs which were continuing from the core study or that started after the end of core study but prior to first dose of open-label study medication in the extension study for Category 1 participants are shown under ‘Prior to Ext. first dose’.
AEs which started during the open-label treatment period are presented based on the last AFQ056 dose taken on or before the onset date of the AE (25 mg bid; 50 mg bid; 75 mg bid; or 100 mg bid). No efficacy data presented as study was terminated.</description>
          <population>The analysis was performed in the safety set (SS) population, defined as participants who received at least one dose of study medication and had at least one safety assessment occurring after first dose of extension study medication. Here, ‘Number of Participants Analyzed’ signifies those participants who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="118"/>
                <count group_id="O5" value="116"/>
                <count group_id="O6" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious or significant AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued due to non serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prior to Ext.First Dose</title>
          <description>Prior to Ext.first dose</description>
        </group>
        <group group_id="E2">
          <title>AFQ056 25 mg Bid</title>
          <description>AFQ056 25 mg bid</description>
        </group>
        <group group_id="E3">
          <title>AFQ056 50 mg Bid</title>
          <description>AFQ056 50 mg bid</description>
        </group>
        <group group_id="E4">
          <title>AFQ056 75 mg Bid</title>
          <description>AFQ056 75 mg bid</description>
        </group>
        <group group_id="E5">
          <title>AFQ056 100 mg Bid</title>
          <description>AFQ056 100 mg bid</description>
        </group>
        <group group_id="E6">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="103" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single­ site are postponed until the publication of the pooled data (i.e, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862­-778­-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

